This site uses cookies to bring you the best experience. Find out more
Skip to main content
↑

News

Find Out The Latest

Keep in touch with exciting developments from The Oxford Science Park and its occupiers here.

Contact us on comms@oxfordsp.com if you would like to know more about any of these stories.

You can also follow us on LinkedIn  

Immunocore announces closing of $75.0 Million Series C round

Immunocore announces closing of $75.0 Million Series C round

11 Jan 2021

Funding follows positive Phase 3 trial interim analysis data for tebentafusp in patients with metastatic uveal melanoma (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 11 January 2021) Immunocore, a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune... Read more

Exscientia launches Miami Office to recruit US-based Technology talent as part of continued expansion

Exscientia launches Miami Office to recruit US-based Technology talent as part of continued expansion

04 Jan 2021

Exscientia, the world-leading artificial intelligence (AI) driven Pharmatech company, today announces the opening of its US based Miami office, with recruitment starting immediately. Led by Chief Research Engineer, Adrian Schreyer, Exscientia are recruiting both AI Engineers and Cheminformaticians to join the new Miami office. Members of the team will have extensive opportunities to work in the globally important field of... Read more

Oxford University & Vaccitech welcome UK regulatory emergency use authorisation of coronavirus vaccine

Oxford University & Vaccitech welcome UK regulatory emergency use authorisation of coronavirus vaccine

30 Dec 2020

Oxford, UK – Vaccitech Ltd announces that the UK Government has today accepted the recommendation from the Medicines and Healthcare products Regulatory Agency (MHRA) to authorise the emergency use of the ChAdOx1 nCoV-19 coronavirus vaccine in the UK. The vaccine was co-invented by Vaccitech and The University of Oxford’s Jenner Institute. The Joint Committee on Vaccination and Immunisation (JCVI)... Read more

Enara Bio relocates to The Oxford Science Park’s newest facility to expand R&D capabilities in the search for novel cancer immunotherapies

Enara Bio relocates to The Oxford Science Park’s newest facility to expand R&D capabilities in the search for novel cancer immunotherapies

09 Dec 2020

Oxford and London, UK – 9th December 2020. Enara Bio, a biotechnology company leveraging its proprietary T-cell/T-cell receptor (TCR) discovery and Dark Antigen™ platforms to deliver targeted cancer immunotherapies, announces its expansion and move to the new Bellhouse Building at The Oxford Science Park. Enara’s move from the Oxford BioEscalator to one of the UK’s largest biomedical innovation centres is in preparation for its future growth... Read more

Innovate UK backs ATDBio & University of Oxford research in single-cell sequencing

Innovate UK backs ATDBio & University of Oxford research in single-cell sequencing

08 Sep 2020

New approach expected to increase use of technique in research and diagnosis Oxford, UK, September 8 2020 – ATDBio, a leader in complex oligonucleotide synthesis, and a research team at the Botnar Research Centre, University of Oxford, have been awarded funding by Innovate UK, the UK’s Innovation Agency, to improve single-cell RNA sequencing (scRNA-Seq). By developing new materials for scRNA-Seq, the partners expect to increase its use in... Read more

The Daubeny Project

Imaginative design, inspiring spaces.

450,000 sq ft of
premium lab space
completing 2026

Discover More